Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

NASDAQ:NERV opened at $2.31 on Wednesday. The stock has a 50 day moving average price of $2.23 and a 200 day moving average price of $2.54. The stock has a market cap of $16.15 million, a PE ratio of -5.25 and a beta of 0.11. Minerva Neurosciences has a one year low of $2.03 and a one year high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.